MedTrace Logo

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

NCT03430037 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-11

No results posted yet for this study

Summary

This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.

Conditions

  • Frail Elderly Syndrome

Interventions

DIETARY_SUPPLEMENT

Fisetin

Flavonoid Family

DRUG

Placebo oral capsule

Placebo

Sponsors & Collaborators

Principal Investigators

  • Robert J Pignolo, MD, PhD · Mayo Clinic

  • Sundeep Khosla, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-06
Primary Completion
2026-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03430037 on ClinicalTrials.gov